Wednesday, June 24, 2015

EyewireTV — Ophthalmic Innovator Robert Sinskey, MD, is Remembered; Long-Term Argus II Results

In this week's EyewireTV, world-renowned cataract surgeon, inventor, and pioneer Robert Sinskey, MD, passes away; and long-term results of a clinical trial examining the Argus II Retinal Prosthesis System are released for the first time. Also, Imprimis Pharmaceuticals acquires the rights to novel proprietary sedation and anesthesia formulations that are administered under the tongue during ocular and other surgical procedures. (1990 Views)

Watch Video

Wednesday, June 17, 2015

EyewireTV — Live Coverage of OC Ophthalmology Technology Summit, New Rhopressa Trial

In this week's EyewireTV, the FDA allows Aerie Pharmaceuticals to change the primary endpoint range of its second phase 3 registration trial of glaucoma candidate Rhopressa; and Lensar receives CE Mark approval in Europe for its Streamline application upgrades. In the feature, some of the industry’s top business leaders at the Orange County Ophthalmology Technology Summit in Costa Mesa, California, share their thoughts on what they believe are the best investment opportunities in ophthalmology. (2267 Views)

Watch Video

Wednesday, June 10, 2015

EyewireTV — QLT Buys InSite, Zeiss Developing OCT Angiography

In this week's EyewireTV, Canadian biotechnology company QLT signs a definitive agreement to buy InSite Vision in an all-stock deal; and Carl Zeiss Meditec announces it is developing OCT angiography for spectral-domain and swept-source platforms. Also, new research shows that people who wear contact lenses have different microorganisms living on the surface of their eyes than those who do not, possibly explaining why they tend to have more eye infections. (2716 Views)

Watch Video

Wednesday, June 03, 2015

EyewireTV — Glaucoma Pharma Study, Severe Vision Loss-Poverty Link

In this week’s EyewireTV, a Market Scope report reveals that, after years of decline, the global glaucoma pharmaceutical market is expected to climb significantly over the next 5 years due to robust growth in the emerging markets; and a study by the Centers for Disease Control and Prevention shows that there is a significant correlation between severe vision loss and counties located in the southern United States that have high poverty levels. Also, microscope maker Leica Microsystems signs a definitive agreement to acquire Bioptigen, a provider of OCT technology. (2635 Views)

Watch Video

Wednesday, May 27, 2015

EyewireTV — Omidria Recommendation, Pediatric Visual Impairment Study

In this week’s EyewireTV, a month after the commercial launch of Omidria (phenylephrine and ketorolac injection 1%/0.3%) in the United States, European drug regulators have recommended the agent for use during lens replacement surgery; and a large British study of children aged 7 to 9 finds that visual impairment is rarely the cause of pediatric reading problems. Also, Nidek launches the GYC-500 Vixi Green Scan/GYC-500 Green Laser photocoagulator. (3047 Views)

Watch Video

Wednesday, May 20, 2015

Phase 3 Dry Eye Drug Candidate Results, Fovista Update

In this week's EyewireTV, Eleven Biotherapeutics announces that its lead dry eye drug candidate (EBI-005) did not meet either of the two coprimary endpoints in a phase 3 study; and Ocular Therapeutix plans to submit a new drug application to the FDA for its postsurgical ocular pain drug candidate OTX-DP (Dextenza). Also, Ophthotech provides an update and timing projections on its Fovista phase 3 program, which consists of three clinical trials to evaluate the safety and efficacy of Fovista for the treatment of wet AMD. (2217 Views)

Watch Video

Wednesday, May 13, 2015

EyewireTV — Ebola Virus in Eye, AMO iDesign Clearance

In this week's EyewireTV, a report published online in the New England Journal of Medicine reveals that the Ebola virus remained live in the aqueous humor of an Ebola survivor for more than 2 months after recovery; and Abbott Medical Optics receives FDA clearance for the iDesign Advanced Wavescan Studio system for use in LASIK procedures. Also, Regeneron reports that sales of its blockbuster drug Eylea (aflibercept) increased 51% in the United States to $541 million in the first quarter of 2015. (2774 Views)

Watch Video

Wednesday, May 06, 2015

EyewireTV — Ophthalmic Executives Provide Company Updates

In this week's EyewireTV, several executives at the Ophthalmology Innovation Summit in San Diego speak to EyewireTV about the main product candidates in their companies' pipelines. (2447 Views)

Watch Video

Wednesday, April 29, 2015

EyewireTV — Rhopressa Misses Phase 3 Endpoint, Shire CEO Interview

In this week's EyewireTV, Aerie Pharmaceuticals reports that its phase 3 trial of once-daily Rhopressa did not meet its primary efficacy endpoint of demonstrating noninferiority of IOP-lowering compared with twice-daily timolol; and the FDA clears the mVT Service, the first ophthalmic app designed to monitor AMD and diabetic retinopathy. In the feature, Flemming Ornskov, MD, chief executive officer of Shire, talks about the company’s increased focus on the ophthalmology market and the potential for lifitegrast to address an unmet need in the dry eye space. (2730 Views)

Watch Video

Wednesday, April 22, 2015

EyewireTV — Industry News Roundup From the ASCRS Meeting in San Diego

In this week's EyewireTV, AcuFocus receives FDA approval for the Kamra inlay for the surgical correction of presbyopia; and Alcon releases a software upgrade for the LenSx laser system that allows for customized flap creation. Also, Abbott Medical Optics launches a new phaco system called the Compact Intuitiv. (4204 Views)

Watch Video

Tuesday, April 14, 2015

EyewireTV — Lifitegrast Priority Review, Launch

In this week's EyewireTV, Shire achieves a key milestone as the FDA grants priority review designation for the company's dry eye treatment candidate, lifitegrast; and, an online marketplace designed to allow practitioners to learn, compare, rate, and purchase eye care technology, launches. Also, Ellex Medical introduces its multicolor scanning photocoagulator, Integre Pro Scan, in the United States. (2520 Views)

Watch Video

Wednesday, April 08, 2015

EyewireTV — Omidria Launch, Phase 3 Postoperative Product Candidate Results

In this week's EyewireTV, Omeros announces the commercial launch in the United States of its lead eye drug Omidria (phenylephrine and ketorolac injection 1%/0.3%); and in a second phase 3 study, Ocular Therapeutix's product candidate, OTX-DP (sustained-release dexamethasone 0.4mg), meets the primary endpoint of absence of pain, but does not meet the primary endpoint of absence of inflammation. Also, Kala Pharmaceuticals announces positive top-line results from the phase 3 evaluation of its postoperative pain and inflammation drug candidate, KPI-121 (nanoparticle loteprednol etabonate MPP). (2473 Views)

Watch Video
Load More